GEMINI

About Revelation Biosciences

Revelation Biosciences is a public, clinical-stage biotech company leveraging a platform of innate immune modulators to address conditions driven by dysregulated inflammation. The company's lead candidate, GEMINI, is in clinical development and has recently reported positive data from its PRIME study. With a focus on reprogramming immune responses, Revelation targets a broad range of high-need indications but operates in a highly competitive and capital-intensive sector, as evidenced by its pre-revenue status and recent reverse stock split.

Therapeutic Areas